Work

Daratumumab Efficacy in Steroid-Resistant Nephrotic Syndrome Correlates with CD38+ B-Cell Depletion

Year: 2025

Type: article

Abstract: The anti-CD38 monoclonal antibody daratumumab, alone or with anti-CD20 rituximab, can induce remission in steroid-resistant (SRNS) or multidrug-dependent (MDNS) nephrotic syndrome.1 However, the immune correlates of response remain poorly defined.

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2025.07.038

Authors: Carolina Bigatti, Andrea Angeletti, Xhuliana Kajana, Gianluca Caridi, Paolo Cravedi

Institutions: Istituto Giannina Gaslini, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Renal Diseases and Glomerulopathies

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,800